This Medudy course is a video tutorial for physicians on the topic of "Perioperative chemotherapy for muscle-invasive bladder cancer". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
The optimal perioperative chemotherapy for muscle-invasive bladder cancer has not been defined. The VESPER trial compared dose-intensive methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) therapy with gemcitabine and cisplatin (GC) in patients receiving neoadjuvant therapy
Improved and progression-free 3-year survival was reported with the MVAC regimen, but not for the entire perioperative setting. This article focuses on the secondary endpoints, namely overall survival and time to death from bladder cancer at five-year follow-up.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this training you will know:
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
